Search results

1. Where Inhibition is not Enough- Development of Innovative Compounds for Targeted Degradation of Extracellular and Membra…

Principal investigator: dr Marcin Skoreński

Politechnika Wrocławska

Call: OPUS 28 (LAP), Panel: NZ5

2. Development and characterization of novel multitargeted organometallic tubulin polymerization inhibitors for enhancing t…

Principal investigator: dr hab. Damian Nestor Plażuk

Uniwersytet Łódzki

Call: OPUS 27, Panel: NZ7

3. New biocatalytic systems: carbon nanomaterial - enzyme, with controlled activity and potential application in anticancer…

Principal investigator: Paulina Erwardt

Uniwersytet Mikołaja Kopernika, Wydział Chemii

Call: PRELUDIUM 14, Panel: ST5

4. System engineering approach to modeling, analysis and prediction of outcome of combined anticancer therapies

Principal investigator: prof. Andrzej Świerniak

Politechnika Śląska, Wydział Automatyki, Elektroniki i Informatyki

Call: OPUS 11, Panel: ST7

5. New drug carriers in targeted anticancer therapy

Principal investigator: prof. Artur Piotr Terzyk

Uniwersytet Mikołaja Kopernika, Wydział Chemii

Call: OPUS 1, Panel: ST5

6. Iron chelators- the novel approach to anticancer therapy

Principal investigator: Maciej Michał Serda

UNIWERSYTET ŚLĄSKI, Wydział Matematyki Fizyki i Chemii

Call: PRELUDIUM 1, Panel: NZ4

7. Dual cell cycle blockade and immune checkpoint inhibition as a potential strategy of sequential anticancer therapy

Principal investigator: Alicja Stanisława Słota

Uniwersytet Jagielloński

Call: PRELUDIUM 24, Panel: NZ7

8. Potential pharmacological strategies aimed at alleviating cognitive dysfunctions accompanying oncological therapy while …

Principal investigator: dr hab. Joanna Monika Wierońska

Instytut Farmakologii PAN

Call: OPUS 26, Panel: NZ5

9. Anticancer potential of TMPyP4 porphyrin in breast cancer photodynamic therapy and evaluation of the treatment safety

Principal investigator: prof. Błażej Rubiś

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: OPUS 25, Panel: NZ7

10. Pancreatic cancer oxygenation as a prognostic marker during anticancer therapy

Principal investigator: dr Martyna Krzykawska-Serda

Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

Call: OPUS 23, Panel: NZ5

11. STING protein activation combined with anti-vascular agent as a novel strategy for anticancer therapy

Principal investigator: dr hab. Ryszard Smolarczyk

Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach

Call: OPUS 16, Panel: NZ5

12. The new tools for research mechanisms of anticancer activity of photosenthisisers used for photodynamic therapy of cance…

Principal investigator: dr hab. Marek Arkadiusz Murias

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Farmaceutyczny

Call: OPUS 8, Panel: NZ5

13. Effect of dietary modulation of RAGE/AGE axis on prostatic neuroendocrine differentiation and the efficacy of anticancer…

Principal investigator: dr Wawrzyniec Dobrucki

Gdański Uniwersytet Medyczny

Call: OPUS 29, Panel: NZ7

14. Development of novel 1,3-selenazol-2-one derivatives incorporated into self-emulsifying drug delivery systems as a strat…

Principal investigator: dr hab. Robert Czarnomysy

Uniwersytet Medyczny w Białymstoku

Call: OPUS 29, Panel: NZ7

15. Human exosomes as natural carriers of protein kinase CK2 inhibitors and degraders in targeted anticancer therapy.

Principal investigator: dr hab. Patrycja Joanna Wińska

Politechnika Warszawska

Call: OPUS 28 (LAP), Panel: NZ5

16. Canonical and non-canonical roles of DDK in oncogenesis: a cornerstone for the development of novel, potent anticancer t…

Principal investigator: dr Jan Marian Suski

Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

Call: SONATA BIS 14, Panel: NZ3

17. Myeloid cell subpopulations as a source of effector cells for anticancer therapies using CAR chimeric receptors

Principal investigator: dr hab. Angelika Muchowicz

Warszawski Uniwersytet Medyczny, Wydział Lekarski

Call: OPUS 25, Panel: NZ6

18. DNA polymerase θ as a novel therapeutic target in personalized anticancer therapy

Principal investigator: prof. Tomasz Adam Śliwiński

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Call: OPUS 19, Panel: NZ7

19. Investigation on PD-L1 biology for precise shaping of anticancer adoptive therapies

Principal investigator: dr Agnieszka Graczyk-Jarzynka

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Call: SONATA 15, Panel: NZ6

20. Mathematical modelling of drug resistance in anticancer therapies.

Principal investigator: dr Mariusz Piotr Bodzioch

Uniwersytet Warmińsko-Mazurski w Olsztynie, Wydział Matematyki i Informatyki

Call: PRELUDIUM 12, Panel: ST1

21. Nanotheranostics dedicated to targeted anticancer therapies: Novel magnetic hybrid carbon-based materials - synthesis an…

Principal investigator: Artur Kasprzak

Politechnika Warszawska, Wydział Chemiczny

Call: PRELUDIUM 11, Panel: ST5

22. Developing of a new system for targeted anticancer therapy based on betulin derivetive and self-organizing polymeric nan…

Principal investigator: prof. Janusz Edward Kasperczyk

Śląski Uniwersytet Medyczny w Katowicach, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej w Sosnowcu

Call: HARMONIA 7, Panel: ST5

23. Photodynamic therapy combined with PD-1/PD-L1 blockade immunotherapy: new possibilities for the treatment of immunogenic…

Principal investigator: dr hab. Janusz Marcin Dąbrowski

Uniwersytet Jagielloński, Wydział Chemii

Call: OPUS 19, Panel: NZ7

24. Anticancer activity of the thiosemicarbazone derivatives

Principal investigator: dr Anna Dominika Mrozek-Wilczkiewicz

UNIWERSYTET ŚLĄSKI, Wydział Matematyki, Fizyki i Chemii

Call: SONATA 7, Panel: NZ7

25. Natural and synthetic isothiocyanates as a compounds with potential anticancer activity

Principal investigator: Mateusz Psurski

Politechnika Wrocławska, Wydział Chemiczny

Call: PRELUDIUM 1, Panel: NZ4

26. Application of bioconjugation strategy to the synthesis of anticancer Trojan horses

Principal investigator: dr hab. Michał Piotr Antoszczak

Uniwersytet im. Adama Mickiewicza w Poznaniu

Call: OPUS 28, Panel: ST5

27. Bioresorbable, electrospun nonwoven as a multi-drug delivery system for a combination glioblastoma therapy

Principal investigator: dr Monika Anna Musiał-Kulik

Centrum Materiałów Polimerowych i Węglowych PAN

Call: SONATA 17, Panel: NZ7

28. Increasing the precision of chimeric antigen receptor (CAR)-mediated anticancer immunotherapy by using the chemokine-ind…

Principal investigator: dr hab. Radosław Zagożdżon

Warszawski Uniwersytet Medyczny

Call: OPUS 19, Panel: NZ6

29. Integrated multi-omics approach to accelerate anticancer drug discovery by targeting metabolic reprogramming in human co…

Principal investigator: dr hab. Danuta Dudzik

Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny

Call: OPUS 26, Panel: NZ7

30. Novel bispecific G-quadruplex conjugates as potential anticancer agents

Principal investigator: dr Carolina Sofia Pereira Roxo

Instytut Chemii Bioorganicznej PAN

Call: PRELUDIUM 18, Panel: NZ7

31. Dual-targeted biodegradable polymeric micelles for anticancer drug delivery

Principal investigator: dr Katarzyna Jelonek

Centrum Materiałów Polimerowych i Węglowych PAN

Call: SONATA BIS 9, Panel: NZ7

32. Evaluation of the anticancer efficacy of a new chimeric antigen receptor targeting PD-L1 molecule

Principal investigator: dr hab. Radosław Zagożdżon

Warszawski Uniwersytet Medyczny, Wydział Lekarski

Call: OPUS 12, Panel: NZ6

33. New, multifunctional nanoparticles for combined photothermal and gene silencing cancer therapy

Principal investigator: prof. Stefan Jurga

Uniwersytet im. Adama Mickiewicza w Poznaniu, Centrum Nanobiomedyczne

Call: OPUS 11, Panel: ST8

34. Cellular and molecular mechanism of action of PPI dendrimer complexes with nucleoside analogue anticancer drugs

Principal investigator: prof. Barbara Teresa Klajnert-Maculewicz

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Call: OPUS 7, Panel: NZ3

35. Mind the gap! Plasmonic nanocavity for spectroscopic trapping of local molecularrearrangements in DNA upon epigenetic mo…

Principal investigator: prof. Ewelina Wioletta Lipiec

Uniwersytet Jagielloński

Call: OPUS 28, Panel: ST4

36. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p…

Principal investigator: prof. Tomasz Adam Gośliński

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: PRELUDIUM BIS 4, Panel: NZ7

37. Reversible senescence as a new mechanism of cancer cell resistance for chemotherapy. Analysis of the mechanism of cancer…

Principal investigator: dr Karolina Anna Staniak

Politechnika Warszawska, Wydział Chemiczny

Call: SONATINA 5, Panel: NZ3

38. Tyrosine-modified polyethylenimine polymers as a promising vectors for siRNA delivery in synergistic cancer immunotherap…

Principal investigator: Małgorzata Kubczak

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Call: PRELUDIUM 19, Panel: NZ5

39. Foldback triplex-forming oligonucleotides as novel tools for G-quadruplex unfolding and selective inhibition of c-Myc on…

Principal investigator: prof. Anna Pasternak

Instytut Chemii Bioorganicznej PAN

Call: OPUS 19, Panel: NZ7

40. Cellular mechanisms and effects in vivo of selective lactate dehydrogenase A inhibitors in experimental models of mesoth…

Principal investigator: prof. Ryszard Tomasz Smoleński

Gdański Uniwersytet Medyczny, Wydział Lekarski

Call: OPUS 16, Panel: NZ7

41. Evaluation of tumour metabolomic response to imatinib in a study of mouse xenograft models with gastrointestinal stromal…

Principal investigator: Szymon Macioszek

Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny

Call: PRELUDIUM 15, Panel: NZ7

42. Mesenchymal stromal cells (MSC) as carriers of IL-12 cDNA in treatment of mice with melanoma B16-F10 and metastases

Principal investigator: Natalia Iwona Kułach

Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach

Call: PRELUDIUM 9, Panel: NZ4

43. Does cyclic hypoxia specifically affect microRNA expression in human endothelial cells?

Principal investigator: dr Kinga Kochan-Jamrozy

Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej

Call: PRELUDIUM 9, Panel: NZ7

44. Engineering of intelligent inhalable therapeutics with the capacity for guided accumulation and triggered release of act…

Principal investigator: prof. Elżbieta Pamuła

Akademia Górniczo-Hutnicza im. Stanisława Staszica w Krakowie, Wydział Inżynierii Materiałowej i Ceramiki

Call: HARMONIA 6, Panel: ST5

45. From a molecular in silico model to cellular response in vitro. Modified nucleosides as photo and/or radiosensitizers of…

Principal investigator: prof. Janusz Adam Rak

Uniwersytet Gdański, Wydział Chemii

Call: MAESTRO 6, Panel: ST4

46. Studies on the biological activity of selected aminomethylidenebisphosphonic acids

Principal investigator: dr Anna Nasulewicz-Goldeman

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Call: OPUS 7, Panel: NZ4

47. The study of mechanisms that enhance the antitumor activity of 5-FU by the use of vitamin D analogs in human colon cance…

Principal investigator: dr Magdalena Milczarek

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Call: PRELUDIUM 3, Panel: NZ5

48. Combined induction of cell death of canine leukemia and lymphoma.

Principal investigator: dr hab. Andrzej Marek Rapak

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Call: OPUS 2, Panel: NZ5

Projects search